New York based global biopharmaceutical company Bristol Meyers Squibb will invest $100 million to establish a facility in Hyderabad, India, to expand its global drug development and IT capabilities.
The firm plans to begin its operations in Hyderabad in the second half of 2023 and employ approximately 1,500 people. According to a company press release, the site will support the pursuit of therapies at the forefront of scientific discovery, and draw on the dynamic scientific and technology talent
in the region.
Samit Hirawat, chief medical officer, Global Drug Development, said: “The Hyderabad site is a long-term strategic investment, and we look forward to commencing operations later this year. We are excited about the opportunity to diversify our company globally, which will position us to further accelerate our drug development, and advance our mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.”
